Low Intensity Blood Flow Restriction Training Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Low Intensity Blood Flow Restriction Training Study (NCT03055260), a randomized na study. The primary outcome is One Repetition Maximum.

2. Clinical Question

The central statistical question is whether the posted outcome information permits estimation of a difference between the active-cuff and placebo-cuff arms. It does not: the registry reports an active-arm mean and standard deviation, but no placebo-arm participants or measurements. A value for one arm alone describes that arm’s posted results; it cannot establish how the result compares with the alternative cuff condition.

The study description includes baseline testing and repeat testing after the training period. Testing included quadriceps muscle thickness by ultrasound, leg-press 1RM, and isometric knee-extension strength. The primary outcome description names a single-leg press 1RM and also refers to isometric quadriceps extension strength. The record does not clarify whether the posted primary value is intended to represent both measures or only the titled 1RM measure.

Thus, the record provides a description of the intended question and protocol, but its posted primary results do not answer the comparative question. It does not report the placebo-arm outcome, a between-arm estimate, or a statistical test of the arm difference.

3. Trial Design

The registry describes a randomized, parallel-group study with no masking. Participants were assigned to an active blood-flow restriction cuff or a placebo cuff that did not restrict blood flow. The study status is completed, and enrollment is listed as 8. The record gives a start date of 2017-05-23 and a primary completion date of 2018-12-31.

According to the study description, baseline testing assessed quadriceps muscle thickness using ultrasound, leg-press one repetition maximum, and isometric knee-extension strength. Strength measures were to be recorded for the right and left legs. Participants were then to perform leg-press exercise at 30% of 1RM for 6 weeks. Sessions were described as occurring 2x/week and taking approximately 10 total minutes, including 5 minutes for warm up and 5 minutes for the testing protocol. The outcomes were to be retested after the training period.

The registry lists a primary outcome titled One Repetition Maximum, measured in pounds, with a mean and standard deviation as the reported summary type and a 6-week timeframe. Its description mentions both single-leg press 1RM and isometric quadriceps extension strength. Quadriceps muscle thickness is also listed among the secondary outcomes.

The posted primary outcome data report an active-cuff arm with n=7.0, a mean of 302.9, and a standard deviation of 67.1. The placebo arm is listed with n=0.0, with no outcome value or spread. The primary outcome description explicitly says no participants completed the placebo arm. Therefore, although the registry records randomized allocation and a parallel design, the posted endpoint results do not contain completed outcome data for both arms.

The record does not report details such as the randomization sequence, allocation concealment, adherence, reasons for noncompletion, or protocol deviations. It also does not report whether the planned testing schedule was completed as described for each participant. Those details cannot be inferred from the design label or the posted arm summaries.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: No participants completed the placebo arm.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: No participants completed the placebo arm.

6. Primary Endpoint

The registry lists the primary outcome as One Repetition Maximum, measured over 6 weeks.

The primary outcome is titled One Repetition Maximum, with pounds as its unit and a 6-week timeframe. A one repetition maximum is the greatest load a person can lift for one repetition under the specified test conditions. In this study, the description identifies the leg press and also mentions isometric quadriceps extension strength. The study summary describes testing before and after the training protocol, while the posted outcome is presented as a mean and standard deviation for the stated timeframe.

Strength measures are used in exercise studies because they provide a direct performance measure related to the ability to produce force in a defined task. A leg-press 1RM captures performance in that exercise; an isometric extension measure captures force under a different testing condition. These measures are related to lower-extremity strength but are not interchangeable. The registry’s description mentions both, so the precise correspondence between the reported mean and each strength test is not fully clear.

The posted active-arm result is a mean of 302.9 pounds with a standard deviation of 67.1. The standard deviation describes the spread of individual measurements around the group mean; it is not a confidence interval and does not directly quantify uncertainty in the mean. No placebo-arm measurement is reported, so the endpoint record does not provide an estimate of the difference between the cuff conditions.

Quadriceps muscle thickness is listed as a secondary outcome, but no numerical result for it is present in the record. Consequently, the primary strength summary can be described for the active arm, while comparative interpretation and a complete account of the secondary endpoint are unavailable from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a mean with a standard deviation describe?

For a continuous measurement such as strength in pounds, the mean gives the arithmetic average of the recorded values. The standard deviation describes how dispersed those individual values are around the mean. A larger spread indicates more variability among measurements; it does not tell whether the group mean is estimated precisely, and it does not describe the range of all possible outcomes.

The registry reports an active-arm mean of 302.9 and a standard deviation of 67.1. Those summaries are descriptive and refer to the posted active-arm outcome. The mean is not a change score unless the record explicitly identifies it as one. Here the record provides a 6-week timeframe, but does not post a baseline mean or an explicit difference between baseline and follow-up. The value should therefore not be read as the amount of improvement during the study.

A standard deviation must also be distinguished from a standard error and a confidence interval. A standard error concerns the uncertainty of an estimated mean, while a confidence interval expresses a range of values compatible with the data and analysis under its assumptions. Neither is reported for this outcome. A standard deviation alone cannot substitute for either, and no confidence interval for an arm difference can be reconstructed from the registry information.

Why is the missing comparator important?

In a randomized parallel-group trial, the central comparison is generally between outcomes in the assigned arms. A contrast between arm means can estimate the difference associated with assignment, subject to the study’s conduct, outcome measurement, and analysis. The registry lists random allocation and a placebo-cuff arm, but it reports no participants completing that arm for the primary outcome. As a result, there is no observed placebo mean to contrast with the active-arm mean.

This is not merely a matter of a wide confidence interval. When one arm has no recorded outcome participants, the comparative estimate is not available from the posted arm summaries. The skip reason states that values are missing or not estimable for a two-arm comparison of a continuous endpoint. No recalculated comparative result is reported. The descriptive active-arm statistics remain interpretable as a summary of that arm, but they do not answer the randomized treatment question.

Randomization is valuable because, when outcome information is available in the assigned groups and the analysis is appropriate, it can support a fair comparison. It does not itself generate a comparator outcome or overcome the absence of data. Nor can a single arm serve as its own control without suitable repeated-measure data and a prespecified analysis; the registry does not post a baseline-to-follow-up estimate for the primary outcome.

What can be learned from a confidence interval or a test?

In general, a confidence interval communicates the uncertainty around an estimate. A narrow interval indicates greater precision under the statistical model, whereas a wide interval indicates less precision. A hypothesis test evaluates how compatible the observed data are with a specified null hypothesis under its assumptions. Neither a confidence interval nor a p-value alone establishes clinical importance, and neither can replace a well-defined effect estimate.

The registry record does not report a confidence interval, p-value, or analysis for the primary comparison. Consequently, statistical significance cannot be assessed from the posted primary outcome, and the magnitude and precision of a treatment contrast are not available. It would be inappropriate to derive a test result from the active-arm summary alone, because there is no comparator outcome to use in that comparison.

How should the analysis plan be understood?

The registry reports zero analyses for the posted results, and the record does not describe a statistical analysis plan. It does not report whether the primary analysis was intended to compare follow-up values, changes from baseline, or an adjusted model. It also does not report assumptions about missing observations, handling of protocol deviations, or the population intended for analysis. These choices matter because different approaches can target different estimands and make different assumptions.

The study description includes measures collected at baseline and after 6 weeks, but that description is not a substitute for a reported analysis method. A repeated-measures approach could, in general, use within-participant measurements, while an arm comparison could use follow-up values or change scores. Each approach requires suitable data and a defined analytic population. The registry entries do not identify which method, if any, was used.

What does the planning information mean?

In general, sample-size planning asks how many participants per arm would be needed to detect a specified effect under stated assumptions. Such figures are planning illustrations, not observed power and not evidence that a study had adequate power after completion. The registry’s planning assumptions specify a two-sided significance level of 0.05, equal allocation, and a normal approximation, with effects expressed as fractions of the observed effect. The record does not report the trial’s own sample-size justification.

Because a comparative outcome is not available for both arms, any planning calculation based on the observed effect should be treated cautiously. It cannot turn the absent placebo result into evidence about the treatment contrast. A planning illustration describes a hypothetical future design under its assumptions; it does not change what was measured or reported in this trial.

Over-dispersion is a general concern when variability exceeds what a chosen statistical model assumes. For a continuous endpoint, the model must represent the outcome distribution and its variability adequately; for event counts, over-dispersion can make a simple model understate uncertainty. The registry’s primary endpoint is continuous, and no fitted model or dispersion assessment is reported. This is a general statistical consideration, not a claim that over-dispersion occurred in this study.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Blood Flow Restriction Cuff")
n   <- c(7)
m   <- c(302.9)
sp  <- c(67.1)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Blood Flow Restriction Cuff  7  302.900  67.100  240.843  364.957

11. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary outcome of One Repetition Maximum and identifies Quadriceps Muscle Thickness as a secondary outcome. It reports two outcome measures in total, but the available primary summary does not include a numerical secondary result. The record does not report a multiplicity strategy, such as a hierarchy of tests or an adjustment for making more than one statistical comparison. Without an analysis plan and reported tests, the effect of any multiplicity handling cannot be assessed.

Missingness is especially consequential for the primary comparison: the placebo arm has n=0.0 in the posted outcome and no value or spread. The registry says no participants completed the placebo arm, but does not report why, whether the arm had been started, or whether any other endpoint information was collected from those assigned to it. The reason for the absence of these outcome data is not reported in the registry record. No imputation method, sensitivity analysis, or missing-data assumption is reported.

The registry enrollment entry is 8, while the primary outcome arm summary lists n=7.0 for the active arm and n=0.0 for placebo. The adverse-event data list a different at-risk count for the active arm. The record does not explain these differences. They should not be reconciled by adding counts or assuming a particular participant flow.

The analysis population is not reported in the registry record. There is no stated intention-to-treat, per-protocol, or other population definition, and no account of exclusions or deviations from assigned treatment. These omissions limit assessment of whether the posted active-arm summary represents all assigned participants, those who completed the protocol, or another subset. The complete-case and missing-data implications cannot be evaluated from the available results.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event summary lists 8 participants at risk in the active blood-flow restriction cuff arm. It records 0 serious adverse events, 0 other adverse events, and 0 deaths for that arm. The placebo-cuff arm has 0 participants at risk, with 0 serious adverse events, 0 other adverse events, and 0 deaths recorded.

These figures describe what the registry reports; they do not establish that the intervention is free of risk. In particular, the placebo arm has no participants recorded at risk, so its zero event entries do not represent an observed comparison group with exposure. The active-arm figures also need to be interpreted in light of the registry’s limited information about event definitions, ascertainment, follow-up completeness, and reporting procedures. Those details are not reported in the registry record.

The active-arm at-risk count is 8, whereas the primary outcome arm summary lists n=7.0. The record does not explain this difference. Safety denominators and efficacy outcome counts can differ, but the reason for the difference in this record is not reported. The posted event counts should therefore be read as registry summaries rather than as a complete comparative safety analysis.

No serious adverse-event terms are listed. The absence of a reported event in this small record does not answer whether risks differ between cuff conditions or characterize uncommon harms. The data support only the narrow statement that the registry records no serious adverse events, other adverse events, or deaths in the active arm, and no placebo participants at risk.

13. What the Result Does, and Does Not, Mean

The posted result establishes that the registry contains an active-arm mean of 302.9 pounds and a standard deviation of 67.1 for the primary outcome at the 6-week timeframe. It also establishes that the primary outcome record lists n=0.0 for the placebo arm and says that no participants completed that arm. These registry entries allow a descriptive account of the active-arm measurements, but not a randomized comparison of cuff conditions.

The result does not show the amount of change from baseline, because no primary baseline summary or change estimate is posted. It does not estimate the difference between active cuff and placebo cuff, and it does not provide a confidence interval or p-value for such a difference. The one-arm summary cannot establish whether the active cuff changed strength relative to what would have occurred with the placebo cuff. It cannot establish that the intervention worked or failed.

Likewise, the record does not provide a numerical result for the secondary quadriceps muscle-thickness outcome. Although the study description refers to isometric quadriceps extension strength as well as leg-press 1RM, the primary outcome entry does not make the relationship between these measures fully clear. The available outcome information should not be extended to measures for which no numerical result is reported.

The study’s randomized design and completed status are important context, but they do not resolve the lack of comparator outcome data. Statistical conclusions depend on the data and analysis actually reported, not only on the planned allocation. The absent placebo results prevent estimation of the primary between-arm contrast from the registry record.

For readers, the appropriate distinction is between an observed group summary and evidence about a comparative effect. The mean and standard deviation describe the active arm’s posted outcome. They do not quantify treatment benefit, provide uncertainty for a treatment effect, or support conclusions about generalizability beyond the recorded participants. The registry record also does not report enough information to evaluate the reasons for missing comparator outcomes or the population included in the active-arm analysis.

14. Why This Trial Matters Statistically

This study illustrates a basic principle of randomized-trial interpretation: the planned design and the usable outcome data are not the same thing. Random allocation is intended to support comparison between groups, but that comparison requires outcome information for the groups being contrasted. The registry labels the design randomized and parallel, yet the posted primary outcome includes an active-arm summary and no placebo-arm participants. A descriptive result from one arm cannot replace the randomized contrast.

The record also highlights why denominators matter. Enrollment is listed as 8, the primary outcome reports n=7.0 for the active arm and n=0.0 for placebo, and the safety summary lists 8 at risk in the active arm. These are not interchangeable counts. The record does not explain their differences, so readers should preserve the context attached to each rather than combine or interpret them as a participant-flow account.

Outcome definitions matter as well. The primary outcome title identifies 1RM in pounds, while its description also mentions isometric quadriceps extension strength. Those tests represent different measurement tasks. Clear reporting of which measure generated the posted summary is important for reproducibility and interpretation. The registry record does not fully resolve that point.

Finally, a mean and standard deviation are useful descriptive statistics, but they are not a complete inferential analysis. Without a comparator value, effect estimate, uncertainty interval, or reported analysis, readers cannot judge the precision of a treatment contrast. The study is therefore a useful example of how missing outcome information constrains even a trial with a stated randomized design.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation is that the primary outcome has no placebo-arm observations. The posted results therefore do not permit an arm-to-arm estimate, even though the study was registered as randomized and parallel. The record says no participants completed the placebo arm but does not report why or explain what happened after randomization.

The primary outcome entry gives an active-arm mean and standard deviation but no baseline value, change score, confidence interval, p-value, or comparative estimate. It is not possible to determine the direction or magnitude of within-participant change from the posted primary summary. Nor can the precision of a treatment difference be assessed.

The enrollment entry and arm-specific summaries do not align directly: enrollment is listed as 8, the active outcome arm has n=7.0, and placebo has n=0.0. The adverse-event summary lists 8 at risk in the active arm. The registry does not explain these different counts or provide a participant-flow description. The analysis population and handling of missing data are not reported.

The endpoint description combines leg-press 1RM and isometric quadriceps extension strength, while the title emphasizes 1RM. The record does not clarify which measure the posted mean represents. Quadriceps muscle thickness is listed as a secondary outcome, but no numerical result is available in the record summarized for this analysis.

Other details relevant to interpretation are not reported in the registry record, including adherence, reasons for discontinuation, protocol deviations, randomization implementation, analysis methods, and the rationale for the planned enrollment. The record also does not report a multiplicity approach or a statistical analysis plan. These absences restrict assessment of bias, precision, and reproducibility and should not be filled in by assumptions.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Low Intensity Blood Flow Restriction Training Study — NCT03055260.
• Registry record last updated 2020-02-28; status last verified 2020-02.
• Results first posted 2020-02-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03055260 is a completed randomized, unmasked, parallel-group study of low-intensity blood-flow restriction training. Its description compares an active cuff that partially restricts blood flow with a placebo cuff that does not restrict blood flow. The planned exercise protocol used leg presses at 30% of 1RM for 6 weeks, with sessions 2x/week.

The primary outcome is titled One Repetition Maximum, in pounds, at 6 weeks. The active arm is reported with n=7.0, mean 302.9, and standard deviation 67.1. The placebo arm is reported with n=0.0 and no outcome value. The record states that no participants completed the placebo arm, so the primary result is descriptive for the active arm and does not provide a randomized comparison.

Quadriceps muscle thickness is listed as a secondary outcome, but no numerical result is reported in the available record. No comparative analysis, confidence interval, or p-value is reported. The reason for the missing placebo outcome and the analysis population are not reported in the registry record.